Introduction
The serotonergic system has been related to the control of emotional responses and the impairment of serotonin (5-HT) neurotransmission has been classically associated to the pathophysiology of mood disorders. Thus, some pharmacological agents that increase 5-HT synaptic levels exhibit antidepressant properties (Artigas et al, 2002; Nutt et al, 2002) . 5-HT neurons are mainly located within the raphe nuclei. 5-HT is released from the terminals that project to multiple brain regions to regulate several behaviours, including cognition and mood. The removal of 5-HT from the synaptic cleft is carried out by a single protein, the 5-HT transporter (5-HTT). The 5-HTT determines the size and duration of the serotonergic responses, playing a key role in serotonergic neurotransmission (Lesch and Mössner, 2006) . Up to 14 pre-and post-synaptic 5-HT receptors have been identified, which mediate 5-HT responses (Nichols and Nichols, 2008) . 5-HT pre-and post-synaptic receptors also display a regulatory action on the serotonergic activity. Accordingly, the somatodendritic 5-HT 1A autoreceptor negatively controls cell firing and impulse-dependent 5-HT release of serotonergic neurons whereas the axonal 5-HT 1B receptor controls 5-HT synthesis and release at terminal level (Barnes and Sharp, 1999) . Similarly, some post-synaptic receptors such as 5-HT 1A , 5-HT 2A and 5-HT 2C receptors, also participate in the inhibition of 5-HT neurons activity (Hajós et al, 1999; Boothman et al, 2003) . Among all these post-synaptic receptors, growing attention has been addressed toward understanding the role of 5-HT 2C receptor in the regulation of emotional state beyond the involvement in 5-HT feedback regulation. This receptor plays an essential role in the 5-HT-induced hypothalamic pituitary adrenal (HPA) axis activation (Heisler et al, 2007) and also mediates the inhibition of dopaminergic system, a key component for hedonia and motivation (Dremencov et al, 2006) .
Endocannabinoid system is one of the major neuromodulatory systems in the brain and previous studies revealed its contribution on maintaining the homeostasis of various states including mood and emotion (Valverde, 2005; Moreira and Lutz, 2008) . In fact, the pharmacological and genetic blockade of the cannabinoid CB 1 receptor induces a phenotypic state analogous to depression in experimental animals (Hill and Gorzalka, 2005; Aso et al, 2008) . Therefore, CB 1 knockout mice exhibit depressive-like symptoms such as reduced responsiveness to reward stimuli (Sanchís-Segura et al, 2004; Maldonado et al, 2006) , altered neurovegetative functions (Cota et al, 2003) , deficits in extinction of aversive memories (Marsicano et al, 2002 ) and higher anxiety levels and sensitivity to stress than control animals (Martín et al, 2002; Aso et al, 2008) . The role of endocannabinoid system in regulating emotions and mood could be provided by the modulation of neurotransmitter release, including 5-HT, exerted by CB 1 receptors (Tzavara et al, 2003; Szabo and Schlicker, 2005; Bambico et al, 2007) . The interaction between 5-HT and endocannabinoid systems is also sustained by the fact that 5-HT is able to evoke endocannabinoid release (Parrish and Nichols, 2006; Best and Regehr, 2008) . However, further investigations are needed to better understand the interaction between the endocannabinoid system and the different components of the serotonergic system in the modulation of mood and emotions. In this study, we therefore aimed to investigate the role of endocannabinoid system in the regulation of 5-HT neurotransmission by assessing the functionality of some serotonergic components involved in 5-HT feedback in the absence of CB 1 receptor.
Materials and methods

Animals
The experiments were carried out in male CB 1 knockout mice and wild-type littermates 8-12 weeks old at the beginning of the experiments. The generation of mice lacking CB 1 cannabinoid receptor was described previously (Ledent et al, 1999) . In order to homogenize the genetic background of mice, the first generation heterozygous was bred for 30 generations on a CD1 background, with selection for the mutant CB 1 gene at each generation. After the 30 th generation of backcross, heterozygote-heterozygote mating of CB 1 knockout mice produced wild-type and knockout littermates for subsequent experiments. All animals used in a given experiment were matched for age and weight. Mice were housed five per cage in a temperature (21 ± 1ºC) and humiditycontrolled (55 ± 10%) room with a 12:12-h light/dark cycle (light between 08:00 and 20:00 h) with food and water ad libitum. Animal procedures were conducted according to ethical guidelines (European Communities Council Directive 86/609/EEC) and approved by the Local Ethical Committee (PRBB).
Drugs
The selective 5-HT reuptake inhibitor (SSRI) fluoxetine hydrochloride was supplied by Sigma ® Chemical Co (Madrid, Spain). Fluoxetine was dissolved in distilled water and injected intraperitoneally (i.p.) in a volume of 10 mL/kg body weight. The CB 1 receptor antagonist, rimonabant, was kindly provided by Sanofi-Aventis (Bagneux, France).
Rimonabant was emulsified in two drops of Tween 80 and then suspended in saline for i.p. administration in a volume of 10 mL/kg body weight. The 5-HT 1A receptor agonist ipsapirone was purchased by Bayer-Troponwerke (Cologne, Germany).
In vivo microdialysis procedure
Mice were anesthetized with a ketamine/xylazine mixture (0.2 mL/10 g body weight i.p.) and placed in a stereotaxic apparatus with a flat skull (Paxinos and Franklin, 1997) .
A small hole was drilled on the skull and a 2 mm analytical probe (CMA/7/2 mm, CMA Microdialysis, Stockholm, Sweden) was implanted directly in the prefrontal cortex (PFC) (AP, +2.1 mm; ML, ±0.5 mm; DV, −3.0 mm from bregma) and then fixed to the skull with dental cement, as described (Trigo et al, 2007) . One day after probe implantation, animals were habituated to the experimental environment overnight. The following morning, a Ringer solution was pumped through the dialysis probe (NaCl, 148 mM; KCl, 2.7 mM; CaCl 2 , 1.2 mM and MgCl 2 , 0.8 mM, pH 6.0) at a constant rate of 1 μL/min. Five consecutive 18-min dialysis samples were collected for the determination of baseline 5-HT levels. Then, mice were injected with saline or fluoxetine (10 mg/kg, i.p.) and collection of samples was continued for 4 h following injection. Dialysates (15 μL) were injected without any purification into a HPLC system that consisted of a pump linked to an automatic injector (Agilent 1100, Palo Alto, USA), a reverse-phase column (Zorbax SB C18, 3.5 μm, 150×4.6 mm, Agilent
Technologies, Palo Alto, USA) and a coulometric detector (Coulochem II, ESA, Chelmsford, USA) with a 5011A analytical cell. 5-HT was quantified as described (Trigo et al, 2007) . Briefly, the first electrode was fixed at + 50 mV and the second electrode at +300 mV. The gain of the detector was set at 10 nA. The composition of the mobile phase was 50 mM sodium acetate, 0.1 mM Na 2 EDTA, 0.65 mM octane sulfonic acid sodium salt and 24% (vol/vol) methanol, pH 5.0. The flow rate was set at 0.8 mL/min and the sensitivity of the assay for 5-HT was 0.3 pg/15 μL. Percentage of 5-HT concentrations after either fluoxetine or saline challenge respect to basal concentrations were converted to area under the curve (AUC) using a standard trapezoid method (Gibaldi and Perrier, 1975) . 
Electrophysiological experiments
Immediately after removal from the skull, brains were immersed in an ice-cold artificial cerebrospinal fluid (aCSF) (NaCl 126 mM, KCl 3.5 mM, NaH 2 PO 4 1.2 mM, MgCl 2 1.3 mM, CaCl 2 2.0 mM, NaHCO 3 25 mM, D-glucose 11 mM), continuously bubbled with carbogen (95% O 2 , 5% CO 2 ) to maintain pH value at 7.3. A block of tissue containing the dorsal raphe nucleus (DRN) was cut into sections (400 μm thick) in the same aCSF using a vibratome. Brainstem slices were immediately immersed in oxygenated aCSF at room temperature (22 ºC). A single slice was then placed on a nylon mesh, completely submerged in the recording chamber and continuously superfused with oxygenated aCSF (34 ºC) at a constant flow rate of 2-3 mL/min. Extracellular recordings of the firing of DRN serotonergic neurons were made using glass microelectrodes filled with 2 M NaCl (12-15 MΩ). Cells were identified as 5-HT neurons according to previously described criteria (Lanfumey et al, 1999) . Firing was evoked in the otherwise silent neurons by adding the α1 adrenoceptor agonist phenylephrine (3 μM) into the superfusing aCSF (VanderMaelen and Aghajanian 1983) . Electrical signals were fed into a high-input impedance amplifier (VF 180, BioLogic, Claix, France), an oscilloscope and an electronic ratemeter triggered by individual action potentials, connected to an A/D converter and a personal computer. Using dedicated software, the integrated firing rate was recorded, computed, and displayed on a chart recorder as consecutive 10-s samples. Baseline activity was recorded for at least 10 min prior to perfusion of drugs into the chamber, via a three-way tap system. Because complete exchange of fluids occurred within 2 min following the arrival of a new solution into the chamber, the duration of each drug application was 3 min. The effects of the 5-HT 1A receptor agonist ipsapirone were evaluated by comparing the mean discharge frequency during the 2 min prior to its application with that recorded at the peak action of the drug, i.e. 2-3 min after its removal from the perfusing aCSF. Data are expressed as percentages of the baseline firing rates.
Pharmacological treatment
The CB 1 receptor antagonist, rimonabant, and its vehicle were administered i.p. (3 mg/kg) once a day (6:00 p.m.) during 2 weeks to two different groups of wild-type mice. Animals were sacrificed and brains removed for the electrophysiological experiments 18 h after the last rimonabant injection.
In situ hybridization
The protocols for in situ hybridization were based on previously described procedures (López-Giménez et al, 2002; Serrats et al, 2005) . Briefly, an oligonucleotide complementary to 1100-1147 bases of the rat 5-HT 2C receptor cDNA (GenBank acc. 
1994)
Frozen tissue sections were brought to room temperature, air-dried and fixed in 4% paraformaldehyde in phosphate buffered saline (PBS: 8 mM Na 2 HPO 4 , 1.4 mM KH 2 PO 4 , 136 mM NaCl, 2.6 mM KCl), washed once in 3xPBS, twice in 1xPBS, 5 min each, and incubated in a freshly prepared solution of predigested pronase (Calbiochem, San Diego, USA) at a final concentration of 12 U/mL in 50 mM Tris-HCl pH 7.5 and 5 mM EDTA for 2 min at room temperature. The enzymatic activity was stopped by immersion for 30 s in 2 mg/mL glycine in PBS. Tissues were finally rinsed in PBS and dehydrated. The radioactively labeled probe (1.5 nM) was dissolved in the hybridization buffer (50% formamide, 4xSSC, 1x Denhardt's solution, 1% sarkosyl, 10% dextran sulfate, 20 mM phosphate buffer, pH 7, 250 μg /ml yeast tRNA and 500 μg/ml salmon sperm DNA), Tissue sections were covered with hybridization buffer, overlaid with Nescofilm coverslips (Bando Chemical Ind., Kobe, Japan) and incubated overnight at 42 ºC in humid boxes. The sections were then washed in a buffer, in 600 mM NaCl, 10 mM Tris-HCl, pH 7.5, and 1mM EDTA at 60 ºC. For film autoradiography, hybridized sections were exposed to Biomax-MR (Kodak) films for 66h at -70ºC with intensifying screens. Film autoradiograms were scanned with the GS-800 Calibrated Densitometer (Bio-Rad Laboratories, Hercules, USA). The average density of 5-HT 2C mRNA in different brain regions was evaluated semiquantitatively with Quantity One 4.6.3 software (Bio-Rad Laboratories, Hercules, USA).
Statistical analyses
All data are given as means ± SEM. In vivo microdialysis data were analyzed using three-way ANOVA with treatment (saline and fluoxetine) and genotype (wild-type and CB 1 knockout) as between-subjects factors and time after fluoxetine injection as withinsubjects factor and subsequent two-way ANOVA with genotype and treatment as Aso et al between-subjects factors, followed by one-way ANOVA, when required. AUC values were compared by using a between-subjects two-way ANOVA (genotype and treatment), followed by one-way ANOVA for individual differences when required.
Extracellular recordings were analyzed by between-subjects two-way ANOVA (ipsapirone concentration and genotype/chronic treatment) followed by Bonferroni's post hoc t test. Nonlinear regression was carried out using Prism 4.0 software (GraphPad Software Inc., San Diego, CA, USA) for the calculation of EC 50 values of the drugs. Finally, 5-HTT biding and 5-HT 2C receptor expression quantification were analyzed by one-way ANOVA (genotype). In all the experiments, the significance level was set at p < 0.05.
Results
5-HT extracellular levels in the PFC under basal conditions and after acute fluoxetine administration
In vivo microdialysis procedure revealed a significant increase of basal 5-HT extracellular levels in the PFC of CB 1 knockout compared to wild-type mice (F (1, 50) = 4.225, p < 0.05) (Fig 1A) . Consequently, the further 5-HT extracellular levels measure in response to fluoxetine acute administration was expressed as the percentage respect to the basal values for each genotype.
Fluoxetine (10 mg/kg, i.p.) induced an increase in 5-HT extracellular levels in the PFC in both genotypes. However, the CB 1 knockout mice response was lower than wild-type animals ( Fig 1B) . Three-way ANOVA showed a significant main effect of time ( Comparisons between genotypes indicated no differences after saline treatment but lower AUC value in mutant than in wild-type mice after fluoxetine treatment (F (1, 14) = 7.575, p < 0.05). were observed either in the striatum or in the anterior raphe (Fig 2) . (Fig 3A) .
5-HT
However, Bonferroni's post hoc t test indicated a significant difference between genotypes at the ipsapirone 60 nM and 100 nM concentrations (p < 0.05, respectively).
Indeed, the concentration-response curve of ipsapirone in CB 1 mutants was shifted to the right as compared with that for wild-type mice (Fig 3B) The electrophysiological data obtained from the CB 1 knockout mice were in the same line than the results found by the pharmacological blockade of the CB 1 receptor with a chronic treatment with rimonabant (3mg/kg/day, 14 days) (Fig 4A and 4B) . Two-way ANOVA revealed a significant ipsapirone concentration-dependent inhibition (F (6, 96) = 85.250, p < 0.001), a significant effect of rimonabant treatment (F (1, 96) = 12.610, p < 0.001) and a significant interaction between ipsapirone and rimonabant (F (6, 76) = 2.960, p < 0.05) on the firing of serotonergic neurons (Fig 4A) . Bonferroni's post hoc t test indicated a significant difference between vehicle-and rimonabant-treated mice at the ipsapirone 60 nM concentration (p < 0.001). Indeed, the concentration-response curve of ipsapirone in rimonabant chronically treated animals was significantly shifted to the right as compared to vehicle treated mice (Fig 4B) 
Altered 5-HT 2C receptor expression in CB 1 knockout mice
In situ hybridization experiments were carried out to study the distribution of the mRNA coding for 5-HT 2C receptor in the brain of CB 1 receptor knockout and wild-type mice (Fig 5) . Brain sections from both genotypes were included in the same hybridization experiment, and regions to be compared from both groups were exposed to the same β-max film. After the appropriate exposure time, optical densities over the regions of interest were determined for both groups and the values statistically analyzed by one-way ANOVA. A significant decrease in the expression of 5-HT 2C receptor was observed in most of the brain areas examined, including the nucleus accumbens (NAcc) (F (1, 9) = 9.069, p < 0.05), caudate putamen nucleus (CPu) (F (1, 10) = 6.408, p < 0.05), piriform cortex (Pir) (F (1, 10) = 17.264, p < 0.01), paraventricular nucleus of the hypothalamus (PVN) (F (1, 9) = 7.078, p < 0.05), retrosplenial granular cortex (RSG) (F (1, 10) = 12.371, p < 0.01), choroid plexus (ChP) (F (1, 10) = 59.036, p < 0.001), habenula (Hab) (F (1, 9) = 6.855, p < 0.05) and DRN (F (1, 10) = 5.682, p < 0.05). In contrast, a significant increase in the 5-HT 2C receptor expression was observed in the CA3 area of the ventral hippocampus (F (1, 10) = 9.959, p < 0.05). No significant differences were observed in the PFC, lateral amygdala (Amy) or periaqueductal gray (PAG) brain areas.
Discussion
The present study demonstrates that endocannabinoid system through CB 1 receptor modulates the activity of the serotonergic system. In particular, mice lacking CBB 1 receptor exhibited increased 5-HT extracellular levels in the PFC that could be related to alterations of components involved in 5-HT negative feedback, such as 5-HTT, 5-HT 1A and 5-HT 2C receptors.
In vivo microdialysis experiments demonstrated that CB 1 knockout mice display a slight elevation in the basal extracellular 5-HT levels in the PFC. Our observation is in agreement with the moderately increased 5-HT efflux reported in the rat frontal cortex after the administration of the CBB 1 antagonist rimonabant (Tzavara et al, 2003) .
However, the peripheral administration of fluoxetine resulted on lower increase of 5-HT extracellular levels in the PFC of the CB 1 knockout mice compared to wild-type animals, demonstrating that the blockade of CB 1 receptor activity deregulates serotonergic function. In order to raise this issue, we analysed some of the most important mechanisms that control serotonergic feedback in the absence of CB 1 receptor activity.
5-HTT mediates the 5-HT reuptake from the synaptic terminal and determines the size and duration of the serotonergic responses (Lesch and Mössner, 2006) . Radioligand binding approaches revealed that CB 1 knockout mice exhibited a significantly lower 5-HTT binding site density in the frontal cortex and the hippocampus than wild-type mice. This finding could explain in part the decreased response to the fluoxetine treatment observed in mutants in the in vivo microdialysis experiments, given that 5-HTT is the target for the 5-HT reuptake-inhibiting antidepressant compounds such as fluoxetine. In addition, our observation also supports the increased basal 5-HT extracellular levels in the PFC as seems to indicate a reduction in the 5-HT clearance of the synaptic cleft in the absence of CB 1 receptor activity. However, the use of a method such as the no-net-flux technique should be used to confirm a possible reduction of the 5-HT clearance in vivo (Shippenberg et al, 1999) .
The activity of the somatodendritic 5-HT 1A autoreceptor, which negatively controls the firing rate of serotonergic neurons located in the DRN (Barnes and Sharp, 1999) In conclusion, the present results indicate that the lack of CB 1 receptor activity alters 5-HT 1A and 5-HT 2C receptors as well as the 5-HTT density, leading to increased 5-HT extracellular levels as we summarize in Fig 6. Classically, mood disorders have been associated to reduced 5-HT activity basing on the mechanism of action of antidepressant compounds (Charney, 1998; Artigas et al, 2002) . In contrast to what we could expect considering this classical hypothesis, the genetic and pharmacological blockade of the CB 1 receptor induces a depressive-like phenotype (Hill and Gorzalka, 2005; Mangieri and Piomelli, 2007; Aso et al, 2008) . From our point of view, this apparent controversy points out that the chronic absence of CB 1 receptor could impair mechanisms controlling emotional homeostasis beyond 5-HT neurotransmission. Thus, the absence of CB 1 receptor alters the HPA axis activity (Cota, 2008) and neural plasticity that are likely to contribute to emotional disturbances (Berton and Nestler, 2006) . In this sense,
we have previously demonstrated that the enhanced glucocorticoids levels in CB 1 knockout mice could produce hippocampal BDNF impairment, which plays a crucial role on the increased despair behavior exhibited by those mutants (Aso et al, 2008) .
The alterations on 5-HT neurotransmission reported in the present study are supposed to be a substrate for counteracting the stress-induced emotional impairments in mice lacking CB 1 receptor, since similar alterations have been described after antidepressant treatments (Le Poul et al, 2000; Lanfumey et al, 2000; Gould et al, 2006) . Nevertheless, it has been reported an altered post-synaptic serotonergic signalling in CB 1 mutant mice (Mato et al, 2007) that could lead to a reduction in the efficacy of 5-HT for ameliorating their depressive-like phenotype. As a result, the deregulation of glucocorticoid release and the deficiency of neurotrophic mechanisms could prevail upon the alterations on 5-HT neurotransmission, leading to the depressive-like phenotype exhibited by CB 1 mutant mice. However, we can not rule out the possibility that the reduced 5-HTT levels and the 5-HT 1A desensitization reported in the present study could be per se a possible substrate for the depressive-like phenotype exhibited by CB 1 knockout mice.
Thus, an impaired 5-HTT function (Caspi et al, 2003; Olivier et al, 2008) and a 5-HT 1A desensitization (Lesch et al, 1990; Cowen et al, 1994; Bambico et al, 2009 ) have been associated to an increased vulnerability to depressive symptoms in animal models as well as in humans.
In summary, we can conclude that the lack of CB 1 receptor induces an increase in 5-HT extracellular levels by modulating different components of the serotonergic feedback.
These alterations could account for the depressive-like phenotype exhibited by CB 1 knockout mice. Data are expressed as mean ± SEM (n = 5-6). 
